Advertisement
UK markets open in 2 hours 54 minutes
  • NIKKEI 225

    38,374.26
    +171.89 (+0.45%)
     
  • HANG SENG

    18,537.17
    +223.31 (+1.22%)
     
  • CRUDE OIL

    79.46
    +0.47 (+0.60%)
     
  • GOLD FUTURES

    2,319.30
    -3.00 (-0.13%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • Bitcoin GBP

    49,318.78
    -1,008.55 (-2.00%)
     
  • CMC Crypto 200

    1,312.36
    +17.69 (+1.37%)
     
  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     
  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     

Amgen’s Nephrology Drugs: Aranesp, Epogen, Sensipar in 4Q17

Amgen’s Nephrology Drugs: Aranesp, Epogen, Sensipar in 4Q17

In 4Q17, Amgen’s (AMGN) Aranesp generated revenues of $491 million, which reflected a 7% decline on a YoY (year-over-year) basis and a 5% decline quarter-over-quarter. In 4Q17 in the US and international markets, Aranesp generated revenues of $263 million and $228 million, respectively. Lower unit demand and unfavorable changes in foreign exchange rates primarily led to the decline in revenues in 4Q17.